The assets of failed DNA testing firm 23andMe are being bought for $256 million. Biotechnology firm Regeneron Pharmaceuticals said on Monday it would acquire 23andMe's personal genome service, total ...

23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to ...

Regeneron Pharmaceuticals has agreed to acquire nearly all of 23andMe’s assets for $256 million, including its genetic data, following a bankruptcy auction. The deal still needs to be approved by the ...

23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its ...

Matthew Herper covers medical innovation — both its promise and its perils. 23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business ...

DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company’s more than 15 million customers. The former Silicon Valley darling ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

The bankrupt DNA testing firm is being sold to the highest bidder for $256 million. The bankrupt DNA testing firm is being sold to the highest bidder for $256 million. is a news writer focused on ...